RxDoctor Payments Data

Jeffrey Hyde, MD

Interventional Cardiology · Baton Rouge, LANPI 1336143841

Payments from drug & device makers

$4,213in general payments, 2019–2025

Across 242 payments — averaging $17.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$595
  • Johnson & Johnson$476
  • Amgen$410
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$326
  • Medtronic$317
  • Pfizer$216
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,16899%
  • Education$281%
  • Other$170%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,213 in reported general payments places this provider in the 20th percentile of 171 interventional cardiology providers in Louisiana.

See all interventional cardiology providers in Louisiana

Medicare billing

Part B allowed, 2024
$270,488
Medicare patients
1,628
Services billed
4,766

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban419$459,599
EntrestoSacubitril/Valsartan191$244,366
XareltoRivaroxaban100$102,022
Repatha SureclickEvolocumab22$27,758
JardianceEmpagliflozin12$18,474
Metoprolol Succinate540$7,147
Nebivolol Hcl96$4,102
Atorvastatin Calcium381$4,025
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide80$3,383
Rosuvastatin Calcium272$3,337
Amlodipine Besylate501$3,285
Flecainide Acetate62$3,098
Olmesartan Medoxomil138$2,930
Ranolazine ErRanolazine18$2,315
ClopidogrelClopidogrel Bisulfate198$2,226

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$216$459,599419 claims
NovartisEntresto$595$244,366191 claims
Johnson & JohnsonXarelto$476$102,022100 claims
Boehringer IngelheimJardiance$38$18,47412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 171 interventional cardiology providers in Louisiana.

Other interventional cardiology in Baton Rouge

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →